{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:48:27Z","timestamp":1781106507360,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1053\/j.seminoncol.2004.08.007","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"182-190","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S13","title":["Liposomal anthracycline administration and toxicity management: A nursing perspective"],"prefix":"10.1053","volume":"31","author":[{"given":"Laura S.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 13","key":"10.1053\/j.seminoncol.2004.08.007_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.seminoncol.2004.08.010","article-title":"Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials","volume":"31","author":"Alberts","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib2","first-page":"xxx","article-title":"A phase III study of Doxil\/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer","volume":"21","author":"O\u2019Byrne","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib4","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma","volume":"37","author":"Judson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib6","series-title":"Doxil (doxorubicin HCl liposome injection) prescribing information","year":"2001"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib7","series-title":"DaunoXome (daunorubicin citrate liposome injection) prescribing information","year":"2002"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib8","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib9","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6600657","article-title":"Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy","volume":"87","author":"Fallowfield","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0885-3924(03)00070-8","article-title":"Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy","volume":"25","author":"Iconomou","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib12","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2002.07.177","article-title":"Use of epoetin in patients with cancer","volume":"20","author":"Rizzo","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib13","first-page":"72a","article-title":"Prevention and management of Doxil-related side effects","volume":"17","author":"Yee","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 10","key":"10.1053\/j.seminoncol.2004.08.007_bib14","first-page":"54","article-title":"A safety review of pegylated liposomal doxorubicin in the treatment of various malignancies","volume":"11","author":"Alberts","year":"1997","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib15","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1200\/JCO.2001.19.6.1716","article-title":"Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer","volume":"19","author":"Rivera","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0749-2081(99)80010-2","article-title":"Acute hypersensitivity reactions to chemotherapy","volume":"15","author":"Labovich","year":"1999","journal-title":"Semin Oncol Nurs"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","article-title":"Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase 2 trial of liposomal doxorubicin (40 mg\/m(2)) in platinum\/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib20","series-title":"Cancer Symptom Management","first-page":"328","article-title":"Mucositis","author":"Beck","year":"1999"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.08.007_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0749-2081(03)00059-7","article-title":"Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer","volume":"19","author":"Edwards","year":"2003","journal-title":"Semin Oncol Nurs"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib22","first-page":"538","article-title":"Prevention and treatment of oral mucositis following cancer chemotherapy","volume":"25","author":"Wilkes","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib23","first-page":"478","article-title":"Oral toxicity of chemotherapeutic agents","volume":"19","author":"Peterson","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002820-199808000-00007","article-title":"The PRO-SELF Mouth Aware program","volume":"21","author":"Larson","year":"1998","journal-title":"Cancer Nurs"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0959-8049(96)00497-2","article-title":"Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion","volume":"33","author":"Chiara","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF02994097","article-title":"Weekly fluorouracil and high-dose leucovorin","volume":"26","author":"Mortimer","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<965::AID-CNCR23>3.0.CO;2-Y","article-title":"Hand-foot syndrome following prolonged infusion of high doses of vinorelbine","volume":"82","author":"Hoff","year":"1998","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib28","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","article-title":"Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/or metastatic cancer","volume":"16","author":"Mackean","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib29","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin","volume":"15","author":"Ranson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib30","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib31","first-page":"1632a","article-title":"Use of \u201cbag balm\u201d as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents","volume":"20","author":"Chin","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2004.02.019","article-title":"The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma","volume":"93","author":"Molpus","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00216925","article-title":"Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion","volume":"8","author":"Fabian","year":"1990","journal-title":"Invest New Drugs"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.08.007_bib34","first-page":"265b","article-title":"Efficacy of pyridoxine to ameliorate cutaneous toxicity associated with Doxil","volume":"92","author":"Hussein","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib35","first-page":"1567","article-title":"Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes","volume":"4","author":"Vail","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib36","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.1995.13.11.2851","article-title":"Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs","volume":"13","author":"Bertelli","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002800050981","article-title":"Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia","volume":"44","author":"Lopez","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib38","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/1097-0142(197509)36:3<946::AID-CNCR2820360316>3.0.CO;2-5","article-title":"Radiation-adriamycin interactions","volume":"36","author":"Cassady","year":"1975","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00001813-200308000-00011","article-title":"Radiation recall dermatitis induced by pegylated liposomal doxorubicin","volume":"14","author":"Jimeno","year":"2003","journal-title":"Anticancer Drugs"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.08.007_bib41","first-page":"265b","article-title":"Concomitant administration of Doxil and radiation therapy in multiple myeloma patients","volume":"92","author":"Hussein","year":"1998","journal-title":"Blood"},{"issue":"suppl 13","key":"10.1053\/j.seminoncol.2004.08.007_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminoncol.2004.08.006","article-title":"Cardiac safety of liposomal anthracyclines","volume":"31","author":"Ewer","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib43","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (Doxil)","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bjc.6600344","article-title":"A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer","volume":"87","author":"O\u2019Byrne","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.08.007_bib45","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/jnci\/87.20.1556","article-title":"Lack of vesicant injury following extravasation of liposomal doxorubicin","volume":"87","author":"Madhavan","year":"1995","journal-title":"J Natl Cancer Inst"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404003847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404003847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:25:12Z","timestamp":1554337512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404003847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":45,"alternative-id":["S0093775404003847"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.08.007","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}